Should Brazilian patients with chronic hepatitis C virus infection be vaccinated against hepatitis A virus?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 2, 2009, Pages 238-242

  Villar, Livia M ^a   De Melo, Maria M M ^b   Calado, Izabelle A ^b   De Almeida, Adilson J ^a   Lampe, Elisabeth ^a   Gaspar, Ana M C ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Central Public Health Laboratory of Pernambuco State   (Brazil)

Author keywords

Hepatitis A virus; Hepatitis C virus; Vaccination

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; IMMUNOGLOBULIN M;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAZIL; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROLOGY; VACCINATION; VIRUS DETECTION;

EID: 58849088140     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05575.x     Document Type: Article

References (36)

1. Villar LM, da Costa MCE, de Paula VS, Gaspar AMC. Hepatitis A outbreak in a public school in Rio de Janeiro, Brazil. Mem. Inst. Oswaldo Cruz 2002 97 : 301 5.
2. Villar LM, Meyer A, Lampe E, Gaspar AMC. Genetic variability of hepatitis a virus isolates in Rio de Janeiro: implications for the vaccination of school children. Braz. J. Med. Biol. Res. 2004 37 : 1779 87.
3. Morais LM, de Paula VS, Arantes MR, Oliveira ML, Gaspar AM. Early infection and asymptomatic spread of hepatitis A virus in a public child care center in Rio de Janeiro, Brazil: should attending children under two years of age be vaccinated? Mem. Inst. Oswaldo Cruz 2006 101 : 401 5.
4. Vitral CL, Yoshida CFT, Lemos ERS, Teixeira CS, Gaspar AMC. Age-specific prevalence of antibodies to hepatitis A in children and adolescents from Rio de Janeiro, Brazil, 1978 and 1995. Relationship of prevalence to environmental factors. Mem. Inst. Oswaldo Cruz 1998 93 : 1 5.
5. Vitral CL, Gaspar AM, Souto FJ. Epidemiological pattern and mortality rates for hepatitis A in Brazil, 1980-2002 - a review. Mem. Inst. Oswaldo Cruz 2006 101 : 119 27.
6. Clemens SA, da Fonseca JC, Azevedo T et al. [Hepatitis A and hepatitis B seroprevalence in 4 centers in Brazil.] Rev. Soc. Bras. Med. Trop. 2000; 33: 1-10. (In Portuguese.)
7. Keeffe EB, Iwarson S, McMahon BJ et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver diseases. Hepatology 1998 27 : 881 6.
8. Vento S, Garofano T, Renzini C et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N. Engl. J. Med. 1998 338 : 286 90.
9. Lefilliatre P, Villeneuve JP. Fulminant hepatitis A in patients with chronic liver disease. Can. J. Public Health 2000 91 : 168 70.
10. Vento S. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. J. Viral Hepat. 2000 7 (Suppl. 1 7 8.
11. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization practices: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996 45 (RR-15 1 30.
12. Centers of Disease control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006 55 (RR-7 1 23.
13. National Institutes of Health Consensus Development Conference Panel Statement. Management of hepatitis C. Hepatology 1997 26 (Suppl 2S 10S.
14. Keeffe EB. Vaccination against hepatitis A and B in chronic liver disease. Viral Hepat. Rev. 1999 5 : 77 88.
15. American Academy of Pediatrics, Committee on Infectious Diseases. Hepatitis A vaccine recommendations. Pediatrics 2007 120 : 189 99.
16. Saldanha J, Leite N, Health A and the WHO Collaborative Study Group. Establishment of the First International Standard for Nucleic Acid Amplification Technology (NAT) Assays for HCV RNA. Vox. Sang. 1999 76 : 149 58.
17. de Paula VS, Baptista ML, Lampe E, Niel C, Gaspar AM. Characterization of hepatitis A virus isolates from subgenotypes IA and IB in Rio de Janeiro, Brazil. J. Med. Virol. 2002 66 : 22 7.
18. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 1987 4 : 406 25.
19. Felsenstein J. Phylogenetic Inference Package, Version 3.5. Coastalttle, WA : Department of Genetics, University of Washington, 1993.
20. Kumar S, Tamura K, Jakobsen IB, Nei M. MEGA 2: molecular evolutionary genetics analysis software. Bioinformatics 2001 17 : 1244 5.
21. Siddiqui F, Mutchnick M, Kinzie J, Peleman R, Naylor P, Ehrinpreis M. Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy. Am. J. Gastroenterol. 2001 96 : 858 63.
22. Villar LM, Morais LM, Aloise R et al. Co-circulation of genotypes IA and IB of hepatitis A virus in Northeast Brazil. Braz. J. Med. Biol. Res. 2006 39 : 873 81.
23. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int. J. Med. Sci. 2006 3 : 47 52.
24. Ascione A, Tartaglione T, Giuseppe Di Costanzo G. Natural history of chronic hepatitis C virus infection. Dig. Liver Dis. 2007 39 : S4 7.
25. Akriviadis EA, Redeker AG. Acute liver failure A in intravenous drug users with chronic liver disease. Ann. Intern. Med. 1989 110 : 838 9.
26. Devalle S, de Paula VS, de Oliveira JM, Niel C, Gaspar AMC. Hepatitis A virus infection in hepatitis C Brazilian patients. J. Infect. 2003 47 : 125 8.
27. de Paula VS, Lu L, Niel C, Gaspar AM, Robertson BH. Genetic analysis of hepatitis A virus isolates from Brazil. J. Med. Virol. 2004 73 : 378 83.
28. Nainan OV, Armstrong GL, Han XH, Williams I, Bell BP, Margolis HS. Hepatitis A molecular epidemiology in the United States, 1996-1997: sources of infection and implications of vaccination policy. J. Infect. Dis. 2005 191 : 957 63.
29. Costa-Mattioli M, Monpoeho S, Schvoerer C et al. Genetic analysis of hepatitis A virus outbreak in France confirms the co-circulation of subgenotypes Ia, Ib and reveals a new genetic lineage. J. Med. Virol. 2001 65 : 233 40.
30. Tjon GM, Wijkmans CJ, Coutinho RA et al. Molecular epidemiology of hepatitis A in Noord-Brabant, The Netherlands. J. Clin. Virol. 2005 32 : 128 36.
31. Myers RP, Gregor JC, Marotta PJ. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C. Hepatology 2000 31 : 834 9.
32. Rufat P, Dumouchel P, Cadranel JF. Seroprevalence of hepatitis A and cost evaluation of different vaccination strategies against hepatitis A virus in patients with chronic hepatitis C in France. Gastroenterol. Clin. Biol. 2001 25 : 256 60.
33. Lau DT, Hewlett AT. Screening for hepatitis A and B antibodies in patients with chronic liver disease. Am. J. Med. 2005 118 : 28S 33S.
34. Hussain Z, Das BC, Husain SA, Murthy NS, Kar P. Increasing trend of acute hepatitis A in north India: Need for identification of high-risk population for vaccination. J. Gastroenterol. Hepatol. 2006 21 : 689 93.
35. Joshi N, Rao S, Kumar A, Patil S, Rani S. Hepatitis A vaccination in chronic liver disease: is it really required in a tropical country like India? Indian J. Med. Microbiol. 2007 25 : 137 9.
36. Bertino G, Ardiri AM, Bruno MC et al. HAV infection in patients with chronic hepatitis C. Clin. Ter. 2007 158 : 223 5.